首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
Treatment Failure and Post-Artesunate Delayed Haemolysis in a Returned Traveller From Uganda With Partially Drug-Resistant Severe Plasmodium falciparum Malaria 治疗失败和青蒿琥酯后延迟溶血从乌干达部分耐药严重恶性疟原虫疟疾返回的旅行者。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-18 DOI: 10.5694/mja2.70136
Jye Travis, Kate McCarthy, Paul Chapman, Lawrence Huang, Angelica Tan, Qin Cheng, Bridget E. Barber

A man aged in his 40s, recently returned from Uganda, was hospitalised with Plasmodium falciparum malaria, with hyperparasitaemia of ~1.5 × 106 parasites/μL (26%). He received intravenous artesunate followed by artemether–lumefantrine. However, parasite clearance was delayed, and despite a negative blood film following treatment, the patient was readmitted 3 weeks later with recurrent parasitaemia. Further testing for drug-resistant phenotypes and genotypes demonstrated reduced susceptibility to lumefantrine, an A675V mutation in the pfk13 gene and increased ring-stage survival, consistent with partial artemisinin resistance. The case highlights the high risk of P. falciparum treatment failure in patients with hyperparasitaemia and partial drug resistance.

1名40多岁男子,最近从乌干达返回,因恶性疟原虫疟疾住院,伴有高寄生虫血症,约1.5 × 106寄生虫/μL(26%)。他接受了静脉注射青蒿琥酯,随后又接受了蒿甲醚-氨苯曲明。然而,寄生虫清除延迟,尽管治疗后血膜呈阴性,但患者在3周后因复发性寄生虫血症再次入院。对耐药表型和基因型的进一步检测表明,对氟苯曲明(pfk13基因中的A675V突变)的易感性降低,环期存活率增加,与部分青蒿素耐药一致。该病例突出了恶性疟原虫在高寄生虫血症和部分耐药患者中治疗失败的高风险。
{"title":"Treatment Failure and Post-Artesunate Delayed Haemolysis in a Returned Traveller From Uganda With Partially Drug-Resistant Severe Plasmodium falciparum Malaria","authors":"Jye Travis,&nbsp;Kate McCarthy,&nbsp;Paul Chapman,&nbsp;Lawrence Huang,&nbsp;Angelica Tan,&nbsp;Qin Cheng,&nbsp;Bridget E. Barber","doi":"10.5694/mja2.70136","DOIUrl":"10.5694/mja2.70136","url":null,"abstract":"<p>A man aged in his 40s, recently returned from Uganda, was hospitalised with <i>Plasmodium falciparum</i> malaria, with hyperparasitaemia of ~1.5 × 10<sup>6</sup> parasites/μL (26%). He received intravenous artesunate followed by artemether–lumefantrine. However, parasite clearance was delayed, and despite a negative blood film following treatment, the patient was readmitted 3 weeks later with recurrent parasitaemia. Further testing for drug-resistant phenotypes and genotypes demonstrated reduced susceptibility to lumefantrine, an A675V mutation in the <i>pfk13</i> gene and increased ring-stage survival, consistent with partial artemisinin resistance. The case highlights the high risk of <i>P. falciparum</i> treatment failure in patients with hyperparasitaemia and partial drug resistance.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12813300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Can We Ensure Access to Sexual and Reproductive Health Information for Adolescents in Light of Australia's Social Media Restrictions? 鉴于澳大利亚的社交媒体限制,我们如何确保青少年获得性健康和生殖健康信息?
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-15 DOI: 10.5694/mja2.70134
Olena Ivanova, Anisa R. Assifi, Danielle Mazza

Restrictions on social media access for users under 16 years raise a critical question about how adolescents in Australia will access sexual and reproductive health (SRH) information, especially where traditional systems often fall short. Social media has become an important source of SRH education, offering timely and relatable content that bridges gaps left by formal education and healthcare. As access to these platforms is restricted, other pathways must be strengthened. This includes investing in comprehensive in- and out-of-school sexuality education, youth-friendly primary care services and safe digital platforms designed with and for adolescents.

对16岁以下用户使用社交媒体的限制提出了一个关键问题,即澳大利亚的青少年将如何获得性健康和生殖健康(SRH)信息,特别是在传统系统往往不足的情况下。社交媒体已经成为性健康和生殖健康教育的重要来源,提供及时和相关的内容,弥补了正规教育和医疗保健留下的差距。由于进入这些平台受到限制,必须加强其他途径。这包括投资于全面的校内和校外性教育、青年友好型初级保健服务以及为青少年设计的安全数字平台。
{"title":"How Can We Ensure Access to Sexual and Reproductive Health Information for Adolescents in Light of Australia's Social Media Restrictions?","authors":"Olena Ivanova,&nbsp;Anisa R. Assifi,&nbsp;Danielle Mazza","doi":"10.5694/mja2.70134","DOIUrl":"10.5694/mja2.70134","url":null,"abstract":"<div>\u0000 \u0000 <p>Restrictions on social media access for users under 16 years raise a critical question about how adolescents in Australia will access sexual and reproductive health (SRH) information, especially where traditional systems often fall short. Social media has become an important source of SRH education, offering timely and relatable content that bridges gaps left by formal education and healthcare. As access to these platforms is restricted, other pathways must be strengthened. This includes investing in comprehensive in- and out-of-school sexuality education, youth-friendly primary care services and safe digital platforms designed with and for adolescents.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Palliative Care and Quality of End-of-Life Care for People With Terminal Cancer, Victoria, 2018–2023: A Retrospective, Population-Based Cohort Study 晚期癌症患者的早期姑息治疗和临终关怀质量,维多利亚,2018-2023:一项回顾性的、基于人群的队列研究。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-14 DOI: 10.5694/mja2.70128
Chris Schilling, Olivia Wawryk, Anna Collins, Vijaya Sundararajan, Brian H. Le, Jennifer Philip
<div> <section> <h3> Objectives</h3> <p>To determine how many people who die of cancer in Victoria receive palliative care and early palliative care (more than 3 months before death); to assess the impact of early palliative care on the quality of end-of-life care.</p> </section> <section> <h3> Study Design</h3> <p>Retrospective, population-based cohort study; analysis of linked Victorian Cancer Registry data and routinely collected data for inpatient, non-admitted health service and emergency department care during the 12 months prior to death.</p> </section> <section> <h3> Setting, Participants</h3> <p>Victorian adults who died of cancer during 1 January 2018–31 January 2023.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Proportions of people who received palliative care (any time) or early palliative care (more than 3 months prior to death); likelihood of quality of end-of-life care measures: dying outside an acute hospital; chemotherapy, two or more emergency department visits, two or more hospital admissions during final 30 days of life; advance care plan at death.</p> </section> <section> <h3> Results</h3> <p>Of 53,305 people who died of cancer (mean age, 74.8 years [standard deviation, 13.0 years]; 29,527 men [55.4%]), palliative care was provided for 38,697 (72.6%); 17,409 people (32.7%) received early palliative care. The most frequent palliative care type was palliative approach to care (Z51.5 code; 33,974 people, 63.7%). The overall proportion of people who received palliative care did not change markedly during 2018–2022; the proportion who received early palliative care declined slightly, from 34.8% (95% confidence interval [CI], 33.6–35.9) to 33.0% (95% CI, 31.7–33.8). People who received early palliative care were more likely than people who received late palliative care to have an advance care plan (adjusted odds ratio [aOR], 1.46; 95% CI, 1.38–1.55) and to die outside hospital (aOR, 2.50; 95% CI, 2.37–2.64); they were less likely to have two or more of emergency department presentations (aOR, 0.75; 95% CI, 0.70–0.81), two or more hospital admissions (aOR, 0.58; 95% CI, 0.55–0.61) or chemotherapy (aOR, 0.51; 95% CI, 0.47–0.55) during their final 30 days of life.</p> </section> <section> <h3> Conclusion</h3> <p>72.6% of people who died of cancer in Victoria during 2018–2023 had received palliative care, but only 33% had
目的:确定维多利亚州有多少死于癌症的人接受了姑息治疗和早期姑息治疗(死亡前3个月以上);评估早期姑息治疗对临终关怀质量的影响。研究设计:回顾性、基于人群的队列研究;分析维多利亚州癌症登记处的相关数据,以及死亡前12个月内住院、非住院医疗服务和急诊部门护理的常规收集数据。环境,参与者:2018年1月1日至2023年1月31日期间死于癌症的维多利亚州成年人。主要结局指标:接受姑息治疗(任何时间)或早期姑息治疗(死亡前3个月以上)的患者比例;临终关怀措施质量的可能性:在急性医院外死亡;化疗、两次或两次以上急诊科就诊、生命最后30天内两次或两次以上住院;死亡时的预先护理计划。结果:53305例死于癌症的患者(平均年龄74.8岁[标准差13.0岁];男性29527例[55.4%])中,有38697例(72.6%)接受了姑息治疗;17409人(32.7%)接受了早期姑息治疗。最常见的姑息治疗类型为姑息方式护理(Z51.5代码;33974人,占63.7%)。2018-2022年期间,接受姑息治疗的总人数比例没有明显变化;接受早期姑息治疗的比例略有下降,从34.8%(95%可信区间[CI], 33.6-35.9)降至33.0% (95% CI, 31.7-33.8)。接受早期姑息治疗的患者比接受晚期姑息治疗的患者更有可能提前制定护理计划(调整优势比[aOR], 1.46; 95% CI, 1.38-1.55),并在院外死亡(aOR, 2.50; 95% CI, 2.37-2.64);在生命的最后30天内,他们有两次或两次以上急诊科就诊(aOR, 0.75; 95% CI, 0.70-0.81)、两次或两次以上住院(aOR, 0.58; 95% CI, 0.55-0.61)或化疗(aOR, 0.51; 95% CI, 0.47-0.55)的可能性较小。结论:2018-2023年期间,维多利亚州死于癌症的人中有72.6%接受了姑息治疗,但只有33%的人早期接受了姑息治疗。早期提供姑息治疗可以改善临终关怀。尽管早期姑息治疗有可能改善患者的预后,但其早期姑息治疗率很低,这表明需要采取行动。
{"title":"Early Palliative Care and Quality of End-of-Life Care for People With Terminal Cancer, Victoria, 2018–2023: A Retrospective, Population-Based Cohort Study","authors":"Chris Schilling,&nbsp;Olivia Wawryk,&nbsp;Anna Collins,&nbsp;Vijaya Sundararajan,&nbsp;Brian H. Le,&nbsp;Jennifer Philip","doi":"10.5694/mja2.70128","DOIUrl":"10.5694/mja2.70128","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To determine how many people who die of cancer in Victoria receive palliative care and early palliative care (more than 3 months before death); to assess the impact of early palliative care on the quality of end-of-life care.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective, population-based cohort study; analysis of linked Victorian Cancer Registry data and routinely collected data for inpatient, non-admitted health service and emergency department care during the 12 months prior to death.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Victorian adults who died of cancer during 1 January 2018–31 January 2023.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Proportions of people who received palliative care (any time) or early palliative care (more than 3 months prior to death); likelihood of quality of end-of-life care measures: dying outside an acute hospital; chemotherapy, two or more emergency department visits, two or more hospital admissions during final 30 days of life; advance care plan at death.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 53,305 people who died of cancer (mean age, 74.8 years [standard deviation, 13.0 years]; 29,527 men [55.4%]), palliative care was provided for 38,697 (72.6%); 17,409 people (32.7%) received early palliative care. The most frequent palliative care type was palliative approach to care (Z51.5 code; 33,974 people, 63.7%). The overall proportion of people who received palliative care did not change markedly during 2018–2022; the proportion who received early palliative care declined slightly, from 34.8% (95% confidence interval [CI], 33.6–35.9) to 33.0% (95% CI, 31.7–33.8). People who received early palliative care were more likely than people who received late palliative care to have an advance care plan (adjusted odds ratio [aOR], 1.46; 95% CI, 1.38–1.55) and to die outside hospital (aOR, 2.50; 95% CI, 2.37–2.64); they were less likely to have two or more of emergency department presentations (aOR, 0.75; 95% CI, 0.70–0.81), two or more hospital admissions (aOR, 0.58; 95% CI, 0.55–0.61) or chemotherapy (aOR, 0.51; 95% CI, 0.47–0.55) during their final 30 days of life.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;72.6% of people who died of cancer in Victoria during 2018–2023 had received palliative care, but only 33% had","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70128","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Hypoglycaemia Secondary to Chronic Opioid-Induced Hypothalamic–Pituitary–Adrenal Axis Suppression: An Under-Recognised Phenomenon 慢性阿片类药物诱导的下丘脑-垂体-肾上腺轴抑制继发的严重低血糖:一种未被认识的现象。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-14 DOI: 10.5694/mja2.70125
Adam Morton
{"title":"Severe Hypoglycaemia Secondary to Chronic Opioid-Induced Hypothalamic–Pituitary–Adrenal Axis Suppression: An Under-Recognised Phenomenon","authors":"Adam Morton","doi":"10.5694/mja2.70125","DOIUrl":"10.5694/mja2.70125","url":null,"abstract":"","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Newborn Screening: Commodity or Public Good? 新生儿基因组筛查:商品还是公益?
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-14 DOI: 10.5694/mja2.70135
Christopher Gyngell, Sebastian Lunke, Danya Vears, Zornitza L. Stark

Genomic newborn screening (gNBS) can screen for a broad range of genetic conditions, potentially enabling early treatment and improving health outcomes. However, it remains outside publicly funded programmes due to limited evidence and substantial implementation challenges. Offering gNBS in the interim as a fee-for-service option in Australia risks creating inequitable healthcare access, fragmenting care and limiting control over genomic data. Conversely, prohibiting private access may unfairly deny potential benefits to individual infants and families. This article discusses the ethical and practical implications of offering gNBS on a fee-for-service basis prior to a decision being made regarding public funding. Although fee-for-service gNBS undermines equitable access, regulated private offerings by public genomics services could mitigate some of the risks. We emphasise the need for large-scale, well-designed research studies to inform the development and equitable implementation of robust gNBS programmes within public healthcare frameworks.

新生儿基因组筛查(gNBS)可以筛查广泛的遗传疾病,有可能实现早期治疗并改善健康结果。然而,由于证据有限和实施方面的重大挑战,它仍然处于公共资助规划之外。在澳大利亚,暂时将gNBS作为一种按服务收费的选择,可能会造成不公平的医疗保健机会、分散的护理和限制对基因组数据的控制。相反,禁止私人接触可能不公平地剥夺个别婴儿和家庭的潜在利益。本文讨论了在决定是否提供公共资金之前,以按服务收费的方式提供gNBS的伦理和实际意义。虽然按服务收费的gNBS破坏了公平获取,但公共基因组学服务的受监管的私人提供可能减轻一些风险。我们强调需要进行大规模、精心设计的研究,为在公共卫生保健框架内制定和公平实施强有力的gNBS计划提供信息。
{"title":"Genomic Newborn Screening: Commodity or Public Good?","authors":"Christopher Gyngell,&nbsp;Sebastian Lunke,&nbsp;Danya Vears,&nbsp;Zornitza L. Stark","doi":"10.5694/mja2.70135","DOIUrl":"10.5694/mja2.70135","url":null,"abstract":"<div>\u0000 \u0000 <p>Genomic newborn screening (gNBS) can screen for a broad range of genetic conditions, potentially enabling early treatment and improving health outcomes. However, it remains outside publicly funded programmes due to limited evidence and substantial implementation challenges. Offering gNBS in the interim as a fee-for-service option in Australia risks creating inequitable healthcare access, fragmenting care and limiting control over genomic data. Conversely, prohibiting private access may unfairly deny potential benefits to individual infants and families. This article discusses the ethical and practical implications of offering gNBS on a fee-for-service basis prior to a decision being made regarding public funding. Although fee-for-service gNBS undermines equitable access, regulated private offerings by public genomics services could mitigate some of the risks. We emphasise the need for large-scale, well-designed research studies to inform the development and equitable implementation of robust gNBS programmes within public healthcare frameworks.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Impairment Notifications About Doctors to the Australian Medical Regulator, 2012–2022: A Retrospective Cohort Study 2012-2022年澳大利亚医疗监管机构医生健康损害报告:一项回顾性队列研究
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-14 DOI: 10.5694/mja2.70131
Marie M. Bismark, Dilanka Hettiarachchi, Martin Fletcher, Owen Bradfield, Anu Tayal, Yamna Taouk
<div> <section> <h3> Objectives</h3> <p>To assess the prevalence, characteristics and outcomes of health impairment notifications to the Australian Health Practitioner Regulation Agency (Ahpra) and to assess the influence of doctor age, sex, specialty, practice location and country of training on the incidence of health impairment notifications.</p> </section> <section> <h3> Study Design</h3> <p>Retrospective cohort study; analysis of linked de-identified Ahpra medical register and health impairment notifications data.</p> </section> <section> <h3> Setting, Participants</h3> <p>All doctors registered to practise in Australia (except New South Wales) for whom notifications of concerns about physical or mental illness, cognitive decline, substance use disorder or other impairment to safely practising medicine were received by Ahpra during 1 July 2012–30 June 2022.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Health impairment notifications, overall and by notification type and specialty; influence of doctors' characteristics on the incidence of notifications.</p> </section> <section> <h3> Results</h3> <p>During 2012–2022, 112,677 doctors were registered to practise in Australia (other than New South Wales). A total of 1732 health impairment notifications were recorded, including at least one notification for 1258 doctors (1.1%). In multivariable analyses, the incidence of health impairment notifications was higher for male than female doctors (adjusted incidence rate ratio [aIRR], 1.45; 95% confidence interval [CI], 1.26–1.67), for doctors aged 70 years or older than for those aged 30–39 years (aIRR, 2.92; 95% CI, 2.30–3.70) and for doctors in regional (aIRR, 1.33; 95% CI, 1.12–1.58), rural (aIRR, 1.27; 95% CI, 1.03–1.57) and remote areas (aIRR, 1.55; 95% CI, 1.03–2.33) than in metropolitan areas. Among doctors with specialist qualifications, the incidence of notifications was higher for psychiatrists than internal medicine physicians (aIRR, 2.28; 95% CI, 1.62–3.21) and the incidence of substance use notifications was highest for anaesthetists (vs. internal medicine physicians: aIRR, 2.83; 95% CI, 1.66–4.83). Compared with doctors who trained in Australia, doctors who trained in non-comparable jurisdictions were less likely to be subjects of health impairment notifications (aIRR, 0.53; 95% CI, 0.43–0.64). Of 1708 notifications with final Ahpra determinations, 367 (21.5%) resulted in practice restrictions or removal from practice.</p>
目的:评估向澳大利亚卫生从业人员管理机构(Ahpra)通报健康损害的流行程度、特点和结果,并评估医生的年龄、性别、专业、执业地点和培训国家对健康损害通报发生率的影响。研究设计:回顾性队列研究;对关联的去识别Ahpra医疗登记和健康损害通知数据进行分析。环境,参与者:Ahpra在2012年7月1日至2022年6月30日期间收到了所有在澳大利亚(新南威尔士州除外)注册执业的医生对身体或精神疾病、认知能力下降、物质使用障碍或其他安全执业医学损害的担忧通知。主要结果衡量指标:健康损害通报,总体情况以及通报类型和专业情况;医生特征对通报率的影响。结果:2012-2022年期间,112,677名医生在澳大利亚(新南威尔士州除外)注册执业。总共记录了1732份健康损害报告,其中1258名医生(1.1%)至少有一份报告。在多变量分析中,男性医生的健康损害报告发生率高于女性医生(调整发病率比[aIRR], 1.45; 95%可信区间[CI], 1.26-1.67), 70岁或以上的医生的健康损害报告发生率高于30-39岁的医生(aIRR, 2.92; 95% CI, 2.30-3.70),地区(aIRR, 1.33; 95% CI, 1.12-1.58)、农村(aIRR, 1.27; 95% CI, 1.03-1.57)和偏远地区(aIRR, 1.55; 95% CI, 1.03-2.33)的医生的健康损害报告发生率高于大城市地区。在具有专科资格的医生中,精神科医生的通报发生率高于内科医生(aIRR, 2.28; 95% CI, 1.62-3.21),麻醉师的物质使用通报发生率最高(相对于内科医生:aIRR, 2.83; 95% CI, 1.66-4.83)。与在澳大利亚接受培训的医生相比,在非可比辖区接受培训的医生不太可能成为健康损害通知的对象(aIRR, 0.53; 95% CI, 0.43-0.64)。在1708份Ahpra最终裁定通知中,367份(21.5%)导致执业限制或被取消执业资格。结论:健康损害报告很少,但可能对医生造成严重后果。健康损害通报的发生率受医生年龄、性别、专业和地点的影响。考虑到这些因素的具体措施可以支持医生的工作场所健康和安全,并保护患者免受伤害。
{"title":"Health Impairment Notifications About Doctors to the Australian Medical Regulator, 2012–2022: A Retrospective Cohort Study","authors":"Marie M. Bismark,&nbsp;Dilanka Hettiarachchi,&nbsp;Martin Fletcher,&nbsp;Owen Bradfield,&nbsp;Anu Tayal,&nbsp;Yamna Taouk","doi":"10.5694/mja2.70131","DOIUrl":"10.5694/mja2.70131","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To assess the prevalence, characteristics and outcomes of health impairment notifications to the Australian Health Practitioner Regulation Agency (Ahpra) and to assess the influence of doctor age, sex, specialty, practice location and country of training on the incidence of health impairment notifications.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective cohort study; analysis of linked de-identified Ahpra medical register and health impairment notifications data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;All doctors registered to practise in Australia (except New South Wales) for whom notifications of concerns about physical or mental illness, cognitive decline, substance use disorder or other impairment to safely practising medicine were received by Ahpra during 1 July 2012–30 June 2022.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Health impairment notifications, overall and by notification type and specialty; influence of doctors' characteristics on the incidence of notifications.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;During 2012–2022, 112,677 doctors were registered to practise in Australia (other than New South Wales). A total of 1732 health impairment notifications were recorded, including at least one notification for 1258 doctors (1.1%). In multivariable analyses, the incidence of health impairment notifications was higher for male than female doctors (adjusted incidence rate ratio [aIRR], 1.45; 95% confidence interval [CI], 1.26–1.67), for doctors aged 70 years or older than for those aged 30–39 years (aIRR, 2.92; 95% CI, 2.30–3.70) and for doctors in regional (aIRR, 1.33; 95% CI, 1.12–1.58), rural (aIRR, 1.27; 95% CI, 1.03–1.57) and remote areas (aIRR, 1.55; 95% CI, 1.03–2.33) than in metropolitan areas. Among doctors with specialist qualifications, the incidence of notifications was higher for psychiatrists than internal medicine physicians (aIRR, 2.28; 95% CI, 1.62–3.21) and the incidence of substance use notifications was highest for anaesthetists (vs. internal medicine physicians: aIRR, 2.83; 95% CI, 1.66–4.83). Compared with doctors who trained in Australia, doctors who trained in non-comparable jurisdictions were less likely to be subjects of health impairment notifications (aIRR, 0.53; 95% CI, 0.43–0.64). Of 1708 notifications with final Ahpra determinations, 367 (21.5%) resulted in practice restrictions or removal from practice.&lt;/p&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12803957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Hypoglycaemia Secondary to Chronic Opioid-Induced Hypothalamic–Pituitary–Adrenal Axis Suppression: An Under-Recognised Phenomenon 慢性阿片类药物诱导的下丘脑-垂体-肾上腺轴抑制继发的严重低血糖:一种未被认识的现象。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-13 DOI: 10.5694/mja2.70124
Michael Do, Annabelle Hayes, Malgorzata Brzozowska
{"title":"Severe Hypoglycaemia Secondary to Chronic Opioid-Induced Hypothalamic–Pituitary–Adrenal Axis Suppression: An Under-Recognised Phenomenon","authors":"Michael Do,&nbsp;Annabelle Hayes,&nbsp;Malgorzata Brzozowska","doi":"10.5694/mja2.70124","DOIUrl":"10.5694/mja2.70124","url":null,"abstract":"","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Localised Herpes Simplex Following Midline Laparotomy 剖腹切开术后局部单纯疱疹。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-05 DOI: 10.5694/mja2.70122
Jessica S. Bulluss, Paul Chee, Matthew J. Verheyden

An older man with Crohn's disease underwent emergency laparotomy for small bowel perforation. A peri-incisional vesiculobullous eruption developed 5 days later. Histopathology demonstrated viral cytopathic changes, immunohistochemistry was positive for herpes simplex virus and HSV-1 DNA confirmed by polymerase chain reaction test, representing the first reported case of localised herpes simplex following abdominal surgery.

一位患有克罗恩病的老年男子因小肠穿孔接受了紧急剖腹手术。5天后,切口周围出现囊泡性大疱。组织病理学显示病毒细胞病变,免疫组化检测单纯性疱疹病毒阳性,聚合酶链反应试验证实单纯性疱疹1型DNA阳性,这是首次报道的腹部手术后局部单纯性疱疹病例。
{"title":"Localised Herpes Simplex Following Midline Laparotomy","authors":"Jessica S. Bulluss,&nbsp;Paul Chee,&nbsp;Matthew J. Verheyden","doi":"10.5694/mja2.70122","DOIUrl":"10.5694/mja2.70122","url":null,"abstract":"<div>\u0000 \u0000 <p>An older man with Crohn's disease underwent emergency laparotomy for small bowel perforation. A peri-incisional vesiculobullous eruption developed 5 days later. Histopathology demonstrated viral cytopathic changes, immunohistochemistry was positive for herpes simplex virus and HSV-1 DNA confirmed by polymerase chain reaction test, representing the first reported case of localised herpes simplex following abdominal surgery.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption 诊断急性卡瓦皮肤病:1例特征性皮肤疹。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-05 DOI: 10.5694/mja2.70120
Ali Abid, Nicholas Allen, Abeer Hagelamin, Christopher Henderson, Artiene Tatian

A 41-year-old woman presented to the emergency department with a widespread pruritic, erythematous eruption following 6 weeks of kava consumption for anxiety and insomnia. The eruption began on the abdomen and progressively involved the chest, upper back and face. Laboratory investigations revealed mild derangement of liver function test results. Skin biopsy results demonstrated folliculocentric inflammation and necrosis of sebaceous glands, consistent with acute kava dermopathy. Kava, a traditional anxiolytic herbal preparation, has been implicated in both chronic and acute cutaneous reactions, including ichthyosiform and sebotropic eruptions. Its active compounds, kavalactones, are hypothesised to provoke a cytotoxic T-cell–mediated response targeting sebaceous glands. This case is notable as it occurred in an Australian woman with no travel history to the Pacific Islands—a region where kava use is prevalent. Moreover, the distinct histopathological findings, rarely documented in the literature, provide valuable diagnostic insight and serve as a visual reference for clinicians encountering this condition.

一名41岁女性因焦虑和失眠服用卡瓦6周后出现广泛的瘙痒、红斑疹而就诊于急诊室。发病开始于腹部,逐渐累及胸部、上背部和面部。实验室检查显示肝功能测试结果轻度紊乱。皮肤活检结果显示毛囊中心性炎症和皮脂腺坏死,符合急性卡瓦皮肤病。卡瓦是一种传统的抗焦虑草药制剂,与慢性和急性皮肤反应有关,包括鱼鳞状和嗜皮脂性皮疹。它的活性化合物,卡瓦内酯,被假设能引起针对皮脂腺的细胞毒性t细胞介导的反应。这个病例值得注意,因为它发生在一名澳大利亚妇女身上,她没有去过太平洋岛屿的旅行史,而太平洋岛屿是卡瓦使用普遍的地区。此外,独特的组织病理学发现,很少在文献中记录,提供了有价值的诊断见解,并作为临床医生遇到这种情况的视觉参考。
{"title":"Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption","authors":"Ali Abid,&nbsp;Nicholas Allen,&nbsp;Abeer Hagelamin,&nbsp;Christopher Henderson,&nbsp;Artiene Tatian","doi":"10.5694/mja2.70120","DOIUrl":"10.5694/mja2.70120","url":null,"abstract":"<div>\u0000 \u0000 <p>A 41-year-old woman presented to the emergency department with a widespread pruritic, erythematous eruption following 6 weeks of kava consumption for anxiety and insomnia. The eruption began on the abdomen and progressively involved the chest, upper back and face. Laboratory investigations revealed mild derangement of liver function test results. Skin biopsy results demonstrated folliculocentric inflammation and necrosis of sebaceous glands, consistent with acute kava dermopathy. Kava, a traditional anxiolytic herbal preparation, has been implicated in both chronic and acute cutaneous reactions, including ichthyosiform and sebotropic eruptions. Its active compounds, kavalactones, are hypothesised to provoke a cytotoxic T-cell–mediated response targeting sebaceous glands. This case is notable as it occurred in an Australian woman with no travel history to the Pacific Islands—a region where kava use is prevalent. Moreover, the distinct histopathological findings, rarely documented in the literature, provide valuable diagnostic insight and serve as a visual reference for clinicians encountering this condition.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Managerialism on Medical Professionalism: Challenges, Risks and Future Directions 管理主义对医疗职业化的影响:挑战、风险与未来方向。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-12-21 DOI: 10.5694/mja2.70117
Evelyn He, Behnam Shaygi, Anousha Yazdabadi, Christen D. Barras, Paul M. Parizel, Hamed Asadi

Over recent decades, the medical profession has undergone significant changes due to the influence of managerialism, which is characterised by standardisation, efficiency and cost control. Although these principles aim to improve sustainability and transparency within healthcare systems, they often conflict with fundamental aspects of medical professionalism and patient-centred care. This perspective explores how managerialism may negatively affect the medical profession, focussing on its impact on clinician autonomy, the changing nature of medical work, professional identity and collegial relationships within hospital settings. Key challenges faced by doctors include diminishing control over patient care, growing administrative burden, increasing burn-out, erosion of professional values and identity, and fragmentation of collegiality. To address these issues, this perspective advocates for institutional change such as hybrid governance models that integrate professional and managerial expertise to ensure managerial goals remain aligned with clinical realities. Professional bodies and institutions should empower doctors with managerial and leadership competencies to influence organisational change, reconcile clinical and managerial priorities, and uphold professional values and quality patient care within the evolving healthcare landscape. Effective reform requires the considerate integration of managerial systems into healthcare to strengthen, rather than undermine, the professional foundations and ethical values that give medicine its integrity and meaning.

近几十年来,由于管理主义的影响,医疗行业发生了重大变化,其特点是标准化,效率和成本控制。虽然这些原则旨在提高医疗保健系统的可持续性和透明度,但它们往往与医疗专业精神和以患者为中心的护理的基本方面相冲突。这一观点探讨了管理主义如何对医疗行业产生负面影响,重点关注其对临床医生自主性的影响,医疗工作性质的变化,医院环境中的专业身份和学院关系。医生面临的主要挑战包括:对病人护理的控制越来越少、管理负担越来越重、职业倦怠越来越严重、职业价值和身份的侵蚀以及团队合作的分裂。为了解决这些问题,这种观点提倡制度变革,例如将专业和管理专业知识集成在一起的混合治理模型,以确保管理目标与临床现实保持一致。专业团体和机构应赋予医生管理和领导能力,以影响组织变革,协调临床和管理优先事项,并在不断变化的医疗保健环境中维护专业价值观和优质患者护理。有效的改革需要将管理制度周到地整合到医疗保健中,以加强而不是破坏赋予医学完整性和意义的专业基础和道德价值观。
{"title":"The Influence of Managerialism on Medical Professionalism: Challenges, Risks and Future Directions","authors":"Evelyn He,&nbsp;Behnam Shaygi,&nbsp;Anousha Yazdabadi,&nbsp;Christen D. Barras,&nbsp;Paul M. Parizel,&nbsp;Hamed Asadi","doi":"10.5694/mja2.70117","DOIUrl":"10.5694/mja2.70117","url":null,"abstract":"<div>\u0000 \u0000 <p>Over recent decades, the medical profession has undergone significant changes due to the influence of managerialism, which is characterised by standardisation, efficiency and cost control. Although these principles aim to improve sustainability and transparency within healthcare systems, they often conflict with fundamental aspects of medical professionalism and patient-centred care. This perspective explores how managerialism may negatively affect the medical profession, focussing on its impact on clinician autonomy, the changing nature of medical work, professional identity and collegial relationships within hospital settings. Key challenges faced by doctors include diminishing control over patient care, growing administrative burden, increasing burn-out, erosion of professional values and identity, and fragmentation of collegiality. To address these issues, this perspective advocates for institutional change such as hybrid governance models that integrate professional and managerial expertise to ensure managerial goals remain aligned with clinical realities. Professional bodies and institutions should empower doctors with managerial and leadership competencies to influence organisational change, reconcile clinical and managerial priorities, and uphold professional values and quality patient care within the evolving healthcare landscape. Effective reform requires the considerate integration of managerial systems into healthcare to strengthen, rather than undermine, the professional foundations and ethical values that give medicine its integrity and meaning.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1